PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer

Inclusion Criteria: * Patients must have liver-dominant or liver-only metastatic disease from any primary histology; patients with primary hepatocellular or biliary cancer are also eligible * Patients must be clinical candidates for radioembolization with either SIR-spheres or TheraSphere due to metastatic or primary malignancies of the liver * Women of child bearing potential must have a negative serum pregnancy test no more than 72 hours prior to registration * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2 * Ability to understand and willingness to sign a written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of medical information * Complete blood count (CBC) and chemistry panel (CMP) no greater than 4 weeks prior to visit 1 * Diagnostic imaging of the abdomen utilizing either CT with contrast, magnetic resonance imaging (MRI), or PET/CT no greater than 4 weeks prior to visit 1 Exclusion Criteria: * Patients not undergoing radioembolization to the liver * Women of childbearing potential (WOCBP) and men who refuse to comply with appropriate contraception * Women who are either pregnant or breast feeding